Evolus (EOLS) Barclays 27th Annual Global Healthcare Conference summary

Business performance and growth outlook

• Achieved over 30% annual growth for four consecutive years, reaching 32% growth in the latest year.

• Set a goal of at least $700 million in revenue by 2028, with multiple growth vectors identified.

• 2024 revenue guidance is $345–$355 million, with 8–10% expected from the new filler line.

• Exited 2024 with 14% market share, surpassing the 13% target.

• International markets are expected to contribute $100 million to long-term guidance.

Product innovation and market differentiation

• Launched Evolysse, a new injectable HA filler, marking the first new technology in the category in over a decade.

• Evolysse is the first filler with a weight loss indication on its label, targeting GLP-1 and weight loss patients.

• Clinical data shows statistical superiority and longer-lasting results compared to competitors.

• Manufacturing innovation preserves the natural HA structure, appealing to consumers seeking natural outcomes.

• Co-branded media and loyalty programs differentiate the commercial approach.

Commercial strategy and market expansion

• Evolysse launch supported by the Evolus Academy for injector training and a portfolio program offering advantaged pricing and co-branded media.

• Consumer loyalty program to include both Jeuveau and Evolysse by Q3 2024.

• Filler launch expected to drive incremental account penetration and unlock further Jeuveau share.

• Research indicates half of non-partner clinics are interested in Evolysse, opening new growth avenues.

• No new geographies required for long-term guidance, but disciplined OUS expansion remains a focus.